Colon carcinoma is one of the leading causes of mortality due to malignancy in Europe and North America (Finkelstein et al., 1993; Chung-Faye et al., 2000) . The presently used methods to treat colon cancer, including surgical operations, chemotherapy and immunotherapy, are not satisfactory, with a large number of patients dying because of recurrent disease. For these reasons there is an urgent need for development of new strategies, including gene therapy. One of the latter is gene-directed enzyme pro-drug therapy (GDEPT) which seems to be a promising approach to treat colon carcinoma (Moolten et al., 1986; Freeman et al., 1996) . In this system of somatic gene therapy, an enzyme of nonmammalian origin introduced into the cancer cell converts a nontoxic drug to a cytotoxic product. Escherichia coli cytosine deaminase (CD) converting 5-fluorocytosine (5-FC) to 5-fluorouracil (Mullen et al., 1994; Huber et al., 1994) or herpes simplex virus thymidine kinase (HSV-TK) transforming an acyclic nucleoside, ganciclovir, to its monophosphate (Moolten et al., 1986; are examples of suicide genes. Successful GDEPT is dependent on the effective and specific expression of such genes only in cancer cells. This can be achieved using tumor cell-specific promoters of genes coding for tumor-associated antigens. A good example of such 5¢transcriptional regulatory elements is carcinoembryonic antigen (CEA) gene promoter used to express the transgene only in tumor cells producing CEA (Richards et al., 1995; Cao et al., 1998; Fichera et al., 1998; Kurane et al., 1998) .
Carcinoembryonic antigen belongs to the immunoglobulin superfamily that includes proteins with important biological functions, e.g. recognition units of the immunological system and adhesion molecules (Holness & Simmons, 1994) . CEA is a cell surface glycoprotein of 180-200 kDa molecular mass, present in low amounts in several types of normal epithelial cells (Cournoyer et al., 1988; Thompson et al., 1991) . Its highly increased expression is most often associated with colon, stomach, pancreas, lung and breast cancers (Shively & Beatty, 1985; Thompson et al., 1991) . Monitoring of CEA serum level has important prognostic value for postoperative surveillance as well as for chemotherapy and immunotherapy efficacy determination (Shiveley et al., 1985; Seregni et al., 1992) .
As it was shown previously, the expression of suicide genes, E. coli CD and HSV-tk, under the transcriptional control of CEA promoter sequences, is limited to CEA-positive colon (Richards et al., 1995; Cao et al., 1999a; 1999b; Ueda et al., 2000) , gastric 1997) , lung (Osaki et al., 1994; Kijma et al., 1999) , pancreatic (DiMaio et al., 1994) and cholangiocarcinoma cells (Tanaka et al., 2000) . In contrast, the CEA-negative lung carcinoma A549 cells (Osaki et al., 1994) , gastric cancer MKN1 cells as well as renal carcinoma RC9406 and cervix carcinoma HeLa cells (Cao et al., 1999a) do not express reporter or suicide genes when their expression is directed by CEA promoter. These data strongly suggest that CEA promoter sequences are active only in CEA-positive cells, fulfilling the criteria for tumor specific targeting of suicide genes. However, in the present study we obtained unexpected results showing that CEA-negative glioblastoma and melanoma cells are highly sensitive to 5-FC when the E. coli CD gene's expression is directed by CEA promoter. (Grunert et al., 1985) for 1 h on ice. After washing, the cells were incubated with fluorescein-isothiocyanate (FITC)-conjugated rabbit F(ab') 2 fragment against mouse immunoglobulins (DAKO) for another hour on ice. The cells were analyzed for positive staining by flow cytometry, using FACScan (BectonDickinson). Five thousand cells were acquired for each datafile. Data were processed and mean fluorescence intensity calculated using WinMDI 2.0.4 (1995). CEA measurement. The level of secreted CEA in culture supernatants of growing tumor cells was quantified using a commercial immunometric assay (Immunolite CEA,É uro/Diagnostic Products Corporation). RNA analysis. Total RNA was isolated from about 10 7 cells with the use of NucleoBond RNA/DNA 400 kit (MarcheryNagel). To remove contaminants of genomic DNA, purified material was digested with Deoxyribonuclease I kit (Sigma-Aldrich). Reverse transcription reactions were performed using Omniscript Reverse Transcriptase, Buffer RT, 0.1 M dithiothreitol (DTT) and Oligo(dT) 12-18, according to the conditions recommended by the manufacturer (Qiagen GmbH). The reaction mixtures for PCR contained: PCR buffer, 2.5 U Taq DNA polymerase (Qiagen GmbH) and 2 mM of each deoxynucleotide (Sigma-Aldrich). CEA 471 bp cDNA fragment was amplified with primers: 5¢-CCG AAG CTT CAG ATG GTG CAT CCC-3¢ (CEA1) and 5¢-CGC GAA TTC CTT GTC CTC CAC GGG T-3¢ (CEA2) (Bionovo). Human hypoxanthine guanine phosphoribosyl transferase (HPRT) 556 bp cDNA fragment was amplified with primers: 5¢-CCG TTC TCC CCT CCA TCG-3¢ (Hprt-1) and 5¢-CAG GTT ACA TGG TGG TGC-3¢ (Hprt-2) (Bionovo). Construction of pBCMGSNeo/CD/CEA vector and transfections. Plasmid pCEA-TK-S containing a 424 bp fragment of human CEA promoter was kindly provide by Dr. Yoshiro Tanio (Osaka University Medical School, Japan). The CEA promoter from pCEATK-S plasmid was obtained by digestion with BglII followed by generating of blunt Vol. 51 Cytosine deaminase/5-fluorocytosine therapy directed by the CEA promoterends with mung bean nuclease and subsequent digestion with SalI. The resulting fragment was ligated into pBluescript SK+ plasmid (Stratagene) digested with SmaI and SalI. To construct pGL3/CEA plasmid the SacI-XhoI fragment from pBluescript SK+/CEA was subcloned into pGL3Basic vector (Promega). Construction of the expression vector encoding E. coli cytosine deaminase under the control of CMV promoter (pBCMGSNeo/CD/CMV) was described earlier (Szala et al., 1996) . To construct a plasmid encoding E. coli cytosine deaminase under the control of CEA promoter, the CMV promoter was removed from pBCMGSNeo/CD/CMV by digestion with XbaI and SalI. The CEA promoter from pBluescript/CEA digested with the same restriction enzymes was then ligated in place of CMV promoter thus generating pBCMGSNeo/CD/CEA vector. Human cell lines were transfected using Fugene 6 Reagent. DNA (4.5 mg in 50 ml of OPTI-MEM) was mixed with 12 ml Fugene 6 Reagent diluted with 100 ml OPTI-MEM. After 30 min at room temperature the solution, diluted with 5 ml OPTI-MEM, was added to 10 6 cells grown in 100-mm culture dishes. After 5-h incubation, the transfection mixture was replaced with fresh complete medium and then after overnight culture replaced again with complete medium containing 1 mg/ml G418 (Gibco BRL) for CX-1, HT-29, A549 and T98G cells, or 0.8 mg/ml G418 for Hs294T cells. After 4-5 weeks individual colonies were isolated and propagated. The cell clones obtained were maintained in the presence of G418 (0.25 mg/ml). Drug sensitivity assay (SRB assay). The sensitivity of tumor cells, native and CD-transfected, to 5-FC was assessed using proliferation assay described by Skehan et al. (1990) . Briefly, cells (5´10 3 /well) were seeded in 96-well plates (Saerstedt) in suitable complete medium. Next day they were incubated with increasing amounts of 5-FC for 72 h. Then the cells were fixed by cold 50% trichloric acid (POCH, Gliwice, Poland). After washing, they were incubated with 0.4% sulforhodamine B (SRB, Sigma-Aldrich) in 1% acetic acid for 30 min, rinsed 4 times with 1% acetic acid and the protein-bound dye was extracted with 10 mM Tris. The absorbance at 540 nm was measured in a Multiscan RC photometer (Labsystem). The experiment was performed in triplicate.
MATERIALS AND METHODS

Cells
RESULTS
CEA promoter activity in human cancer cell lines
The promoter activity was measured in the analyzed cancer cells after their transfection with pGL3/CEA plasmid, using luciferase assay. The highest luciferase activity was found in human colon carcinoma HT-29 cells (Fig. 1) . Also a considerable level of luciferase expression was detected in the second colon carcinoma cell line CX-1, derived from HT-29 cells (Wagner et al., 1992) ; however, the CEA promoter activity was about 3 times lower than in the parental line. Some activity of luciferase was found in lung carcinoma A549 as well as in melanoma Hs294T and glioblastoma T98G cells.
Expression of CEA by tumor cell lines
The expression of CEA on the surface of human cancer cells was studied by flow cytometry. As it was shown previously mAb 26/3/13 bound strongly to human colon carcinoma CX-1 cells (Fig. 2) (Krop-Wątorek et al., 1999) . High binding of this CEA-specific antibody was also observed for HT-29 cells and a lower one to lung carcinoma A549 cells. mAb 26/3/13 did not react with melanoma Hs294T and glioblastoma T98G cells. The data obtained for membrane-bound CEA correlated well with the results obtained for secreted CEA (Table 1) .
RNA analysis by reverse-transcriptase PCR
The presence of the CEA gene transcript in the analyzed cell lines was detected by reverse-transcriptase PCR. Before reverse transcription, isolated total RNA was subjected to digestion with DNase I. To compare the level of expression of CEA mRNA, semi-quantitative PCR with the PCR product for HPRT as an internal standard was used. As expected, CEA transcript was detected in colon cancer cell lines HT-29 and CX-1 (Fig. 3) . Interestingly, no CEA mRNA was detectable in lung carcinoma A549 cells, however, a PCR product obtained with CEA-specific primers was Vol. 51 Cytosine deaminase/5-fluorocytosine therapy directed by the CEA promoter 727
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In vitro 5-FC sensitivity of human cancer cell lines transfected with E. coli CD
The cell-specificity of CD expression under the control of CEA promoter was analyzed in a panel of CEA-producing and non-producing human carcinoma cell lines. The cancer cells were transfected with pBCMGSNeo/CD/CEA or pBCMGSNeo and selected for resistance to G418. Individual neomycin-resistant clones were harvested and expanded, and their sensitivity to 5-FC was analyzed by SRB assay. We found that individual clones derived from either of the analyzed cell lines after transfection with E. coli CD differed profoundly in their resistance to the pro-drug. Independently of the level of CEA expression, there were clones which were totally resistant to 5-FC with the same IC 50 as cells transfected with the vector alone, as well as clones highly sensitive to this pro-drug. The results of growth inhibition studies, after 72 h of incubation in the presence of increasing amounts of 5-FC, for the selected cell clones are shown in Fig. 4 .
DISCUSSION
Successful gene therapy based on drug sensitization is dependent on strong and cell-specific expression of suicide genes. For colorectal carcinoma two such systems, combination of E. coli cytosine deaminase (CD) and 5-fluorocytosine (5-FC) or herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir have been widely studied. It has been shown by several authors that specific expression of CD or HSV-tk genes in colon as well as other cancer cells can be achieved with a vector delivery system containing CEA promoter sequences. A promoter region of 440 bp was originally cloned by Schreve et al. (1990) who showed that this 5¢ regulatory sequence has a higher activity in CEA-positive cells than in the CEA-negative HeLa cells. Consequently this promoter was used in gene therapy to direct the expression of suicide genes in CEA-expressing cells. CEA promoter driven expression of HSV-TK and/or CD was described in pancreatic cancer (DiMaio et al., 1994) , gastric cancer Lan et al., 1996; Ueda et al., 2003) , lung cancer (Osaki et al., 1994) and colon (Fischera et al., 1998) . It was shown further by Cao et al. (1999b) that essentially the same CEA 5¢ transcriptional regulatory sequence located from -309 to +110 bp from the transcription start site gives more stringent cell-specific expression of CEA in comparison with the CEA promoter region encompassing to -135 to +69 bp. A detailed analysis of 5¢ transcriptional regulatory sequences of the CEA gene was performed by Richards et al. (1995) . They have shown that multimerization of the Amplified cDNA samples were electrophoresed in 1% agarose and stained with ethidium bromide. Individual bands represent different dilutions of cDNA templates for HPRT (1, 10 and 100´) and for CEA (1, 10 and 100´). On the right, the sizes of the PCR products are indicated.
promoter sequence -89 to -40 and then ligation of such a sequence with its specific enhancer sequences resulted in an increase in the expression level as well as specificity for CEA-positive cells. However, the specificity of reporter or suicide gene expression directed by CEA promoter was studied in only a few types of CEA-negative cells, namely gastric cancer MKN1 , lung cancer A549 and CADO-LC9 (Osaki et al., 1994) , cholangiocarcinoma SSP-25 , renal carcinoma RC 9406, hepatocellular carcinoma Hep3B (Cao et al., 1999a) , HeLa (Tanaka et al., 1997) and 293 embryonal (Kijma et al., 1999) . In addition, several authors claimed that the use of CEA promoter ensures safety of human gene therapy based on the results obtained from nude mice model. They have shown that the expression of cytosine deaminase is limited only to human tumor xenografts when nude mice implanted with colorectal carcinoma or gastric cancer were inoculated with viral vectors carrying suicide (CD) or reporter (b-galactosidase) genes directed by CEA promoter (Ueda et al., 2003; Cao et al., 1999a; Lan et al., 1998) . These results, however, have to be treated with caution because there is no obvious reason why the CEA promoter of human origin should be expressed in murine tissues, in contrast to human tissues. Vol. 51 Cytosine deaminase/5-fluorocytosine therapy directed by the CEA promoter 729 In our studies on gene therapy of colon carcinoma, the CEA promoter region encompassing -316 to +107 bp (Osaki et al., 1994) was cloned in pBCMGSNeo/CD/CEA plasmid to direct the expression of E. coli CD. In contrast to the authors cited above, we found that not exclusively CEA-positive cells were sensitive to the enzyme/pro-drug therapy with 5-FC. Our experiments revealed that individual clones derived from the CEA-negative cell lines: melanoma Hs294T and glioblastoma T98G after transfection with E. coli CD can differ profoundly in their sensitivity to 5-FC. The IC 50 estimated for several clones of CEA-negative cells were almost the same as for the CEA-positive cells. Interestingly, similar results were obtained by . They showed that among the CEA-negative MKN1 gastric cancer cells transduced with adenovirus vector carrying lacZ gene under the control of CEA promoter a few cells stained positively for b-galactosidase. The presence of just a small fraction of cell clones highly sensitive to 5-FC in a population of cells generally non-sensitive to the drug, should not affect to a great extent the safety of GDEPT therapy with CEA promoter driven expression of CD. However, because of the profound bystander effect of this enzyme/pro-drug system, such rare 5-FC-sensitive cells can cause severe problems by effectively killing surrounding normal cells.
The question remains what are the possible reasons of such unexpected results. T98G glioblastoma and Hs294T melanoma cells do not express membrane bound CEA, however, trace amounts of a secreted form of this glycoprotein were found in culture supernatants. In accordance with these results some promoter activity was also found in these two cell lines. Heterogeneity of cancer cells is a well known phenomenon, so it is possible that a small fraction of cells actually express the CEA gene. This is supported by the presence of CEA transcript as it was shown by RT-PCR. Thus we can expect that in those few cancer cells external CEA promoter introduced into the cells can be activated by the trans-acting elements (transcription factors) present in these cells.
Safety is the major issue in gene therapy, including the use of suicide genes. Our data suggest that the safety of GDEPT therapy with CEA promoter driven expression of therapeutic genes is not so obvious as has been claimed, and much more has to be done before such an approach can reach the stage of clinical trials.
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